Clinical Observation Of Sakubatril/Valsartan In The Treatment Of Heart Failure Reduced Ejection Fraction

ObjectiveTo explore the clinical observation of Sakubatril/Valsartan in the treatment of Heart failure reduced ejection fraction.MethodsFrom January to March 2018,60 patients with heart failure in our hospital were selected,and left ventricular ejection fraction measured by echocardiography was less than 40%.They were randomly divided into two groups,30 cases in one group.The control group received routine heart failure therapy,while the observation group stopped using angiotensin converting enzyme inhibitor/angiotensin II receptor antagonist in routine heart failure therapy and replaced it with sakubatroxatan.Continuous follow-up for 6 months.The objective evaluation criteria of NYHA cardiac function grading,N-terminal pro-brain natriuretic peptide level,echocardiographic data(left ventricular ejection fraction,left ventricular end-diastolic diameter,left atrial diameter),6-minute walking distance and quality of life score of patients with Kansas City cardiomyopathy were compared before and after follow-up.The clinical efficacy and cardiac function of patients during follow-up period were evaluated comprehensively.Results(1)Routine heart failure therapy group: After 6 months follow-up,the follow-up indicators were retested.Blood NT-proBNP concentration and 6-minute walking distance were improved compared with baseline records(P < 0.05).There was no difference in QOL score and echocardiographic index between the Kansas City cardiomyopathy group and the non-Kansas City cardiomyopathy group.(2)Sakubatril/valsartan group: After 6 months of follow-up,the follow-up indicators were retested.The N-terminal pro-brain natriuretic peptide level,6-minute walking distance,QOL score and left ventricular ejection fraction of patients with Kansas City cardiomyopathy in this group were significantly improved compared with baseline records(P < 0.05).(3)Comparisons between the two groups: the N-terminal pro-brain natriuretic peptide level,6-minute walking distance,left ventricular ejection fraction and QOL score of Kansas City cardiomyopathy patients in the observation group were better than those in the control group(P < 0.05).There was no difference in the incidence of major adverse reactions and readmission rates,and no cardiogenic death occurred.ConclusionSakubatril/valsartan have good clinical efficacy,significantly improve cardiac function,improve activity endurance and quality of life of patients,and have high safety.